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Abstract: As programs to prevent and care for HIV-infected persons are scaled-up in Africa, there is the need for con-
tinuous evaluation of the performance of test kits that could best support these programs. The present study evaluated the 
sensitivity, specificity, ease of use, and cost of AWARE 
TM Blood Serum Plasma (BSP) and Oral Mucosal Transudate 
(OMT) Rapid HIV-1/2 test kits using real-time and archived samples of HIV-infected persons from Cameroon. Matched 
whole blood and OMT specimens were collected prospectively from HIV-positive and HIV-negative persons from differ-
ent regions of Cameroon and tested using the AWARE 
TM BSP and OMT test kits, respectively. These results were com-
pared to the gold standard that included a combination of Determine HIV-1/2 and Enzygnost HIV-1/2. The BSP Rapid 
test kit was further evaluated using well characterized panels of HIV-2 and HIV-1 group O samples. Cost and end-user 
analysis of the OMT test kit was done by comparing its actual cost, consumables, safety, bench time and manipulation 
with other test kits. Of the 732 matched samples, 412 (56.3%) and 320 (43.7%) were from females and males, respec-
tively. Of these samples, 23 (3.1%) gave discordant results between Determine HIV-1/2 and Enzygnost HIV1/2 and were 
excluded from the analysis. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of the AWARE
TM BSP were 100%. The AWARE
TM OMT had 98.8% sensitivity, 98.9% specificity, 98.0% PPV 
and 99.4% NPV. The results of a well-characterized archived panel of HIV-2 (n=7) and HIV-1 group O (n=3) samples us-
ing the AWARE
TM BSP Rapid test kit gave 100% concordance. Total per patient cost of the AWARE OMT rapid test kit 
was US$4.72 compared to a mean cost of US $7.33 + 0.11 for the other test kits. Both the AWARE
TM BSP and OMT 
Rapid test kits demonstrated high sensitivities and specificities on all samples tested and were well adapted for use in re-
source-constrained settings with high HIV heterogeneity such as Cameroon. The AWARE 
TM HIV-1/2 OMT Rapid test 
kit appears to be the cheapest, safest and easiest to use compared with other available test kits. 
BACKGROUND 
  There are concerted efforts by multilateral partners and 
international bodies such as the World Health Organization 
(WHO), the Global Fund for AIDS, Tuberculosis, and Ma-
laria (GFATM), the World Bank (WB), and the US Presi-
dent’s Emergency Plan for AIDS Relief (PEPFAR), to make 
antiretroviral drugs (ARVs) available in developing coun-
tries. To meet these goals, there is the need for improved 
strategies to counsel and test millions of people in different 
settings such as the voluntary counselling and testing (VCT) 
sites, antennal clinics, programs to prevent mother-to-child 
transmission (PMTCT), and Point-Of-Care (POC) sites who 
will eventually benefit from ARVs [1-3]. HIV rapid testing 
devices that are easy to use, do not require refrigeration, and 
are less evasive will be very suitable for this purpose. HIV 
rapid test kits have generally been shown to be less expen-
sive to run, portable and with a longer shelf-life. They are 
more adaptable for field use [4, 5] and screening of high risk 
and far-to-reach populations [6] mostly located in resource-
poor settings. In fact, they have reduced the time between  
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testing and release of results to minutes from days or weeks 
when compared with other assays; thus improving the rate at 
which people return for their results. 
  Rapid test kits have been shown in certain settings to be 
incapable of detecting infections by some genetic subtypes 
of the HIV-1 [7-9]. This calls for the need to regularly up-
date diagnostic principles and methods, and the continuous 
evaluation of test kits to make sure that they can detect the 
newly emerging viral strains. 
  Cameroon is particular in terms of the HIV/AIDS pan-
demic because of the high heterogeneity of the virus. The 
two main types of the virus, HIV-1 and HIV-2, and the three 
main groups of HIV-1: Group M (M for Major), Group O (O 
for Outlier), and Group N (N for Non-M / Non-O or New),
 
have been documented in Cameroon [10-15]. The HIV-1 
Group N virus was first discovered in Cameroon and till 
date, it has not been reported elsewhere [15]. This complex 
HIV diversity may have an impact on the effectiveness of 
HIV diagnostic test kits on samples from Cameroon [16]. 
Efforts aimed at scaling up ARV treatment and early identi-
fication and careful orientation of newly HIV-infected persons 
are currently the main objectives of the Cameroonian Na-
tional AIDS Committee. Because of this complex viral di-
versity within its population, there is the need for   
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continuous rapid test kits selection, evaluation and proposal 
of simplified algorithms that could be used for HIV diagnosis 
within its far to reach population particularly those in the 
rural areas. 
  The use of blood as the sole medium for testing for HIV 
can be problematic in some groups of persons such as child-
ren, newborns, immune-compromised and obese individuals 
in whom getting blood samples can be particularly difficult. 
It has been shown that this problem could be eased by using 
other body fluids such as oral fluid [17-19] because its col-
lection involves non-invasive techniques, unlike phlebotomy 
and fingertip pricking. This could be more adaptable in re-
source-poor settings with improved participant acceptability. 
  The aim of this study is to evaluate the sensitivity, speci-
ficity, ease of use, and cost of AWARE 
TM BSP and OMT 
HIV-1/2 Rapid Test kits [20] on whole blood and oral fluid 
using real-time and archived samples from Cameroon. 
MATERIALS AND METHODS 
Study Design and Population 
  Between August 2005 and January 2006, we carried out a 
cross-sectional evaluation of the AWARE BSP and OMT 
HIV-1/2 Rapid test kits during free screening campaigns for 
HIV infection from presumed HIV negative persons attend-
ing voluntary counselling and testing services (VCT) and 
from support groups of known persons living with 
HIV/AIDS (PLWHA) in Cameroon. These individuals were 
recruited from two different locations namely: the Cameroon 
Development Corporation (CDC) plantations, Tiko, a semi-
urban area in South West Province, and Shemka Medical 
Foundation in the Nkolbisson neighborhood of Yaounde, the 
capital city of Cameroon. Initial contacts were made with 
leaders of PLWHA support groups during which the purpose 
of the study was clearly explained. This was followed by a 
larger meeting involving all members of the group and study 
team during which the objectives of the study were further 
explained. A subsequent appointment was taken for sample 
collection and testing. VCT campaigns were also organized 
for sample collection and testing from presumed HIV-
negative persons during the last week of November 2005 as 
part of the activities marking the World AIDS day that oc-
curred on December 1
st 2005. 
Inclusion and Exclusion Criteria 
  Participants were eligible if any of the following criteria 
were met: >15 years of age; known HIV positive status; un-
known HIV status; and willingness to sign an informed con-
sent form. Participants were excluded if they had ever re-
ceived ARV. 
Ethical Considerations 
  This study received approval from the Ethical Review 
Board of the Ministry of Public Health Cameroon. Concern-
ing PLWHA, initial permission was obtained from various 
leaders of the groups, further explanation and clarification 
was obtained during the general assembly. Permission was 
also obtained from the Administration of the VCT centres 
from where participants were recruited. Furthermore, on the 
day the samples were collected, all participants received a 
one-on-one pre-test counselling that was followed by reading 
and signing of consent forms for their acceptance to partici-
pate. Only those who accepted and signed the consent forms 
were enrolled into the study. 
Sample Collection and Testing 
  After collection of minimal socio-demographic informa-
tion, participants were received by laboratory technicians for 
sample collection. Matched whole blood and oral mucosal 
transudate (OMT) specimens were collected from each par-
ticipating individual. Approximately 5 mls of blood were 
collected by venu-puncture into EDTA-anticoagulant tubes 
bearing the corresponding code number of the participant. 
The OMT specimens were collected using the AWARE
TM 
HIV-1/2 OMT collection device provided within the test kit. 
A portion of the whole blood and all of the OMT samples 
were tested on site using the AWARE
 TM HIV-1/2 BSP and 
OMT Rapid test kits. The remaining portion of the blood 
was transported in coolers containing ice packs to the Cen-
tral Laboratory in Yaounde, centrifuged, plasma stored at – 
20 
oC and later tested in parallel using Determine HIV1/2 
rapid (Abbott Laboratories, Japan) and the Enzygnost 
HIV1/2 Integral ELISA (Dade Behring, Germany); the cur-
rent diagnostic algorithm in Cameroon and considered the 
gold standard for this study. All testing was done following 
the recommendations of the test manufacturers’ product in-
sert. 
HIV-2 and HIV-1 Group O Panels 
  In order to determine the sensitivity of the AWARE
 TM 
HIV1/2 BSP on some rare HIV variants common in Camer-
oon, we further tested this kit using  a well characterized 
panel of seven HIV-2 and three HIV-1 group O samples. 
Each of these panels had been well characterized using a 
variety of serologic and virologic assays (U.S. Food and 
Drug Administration). 
Quality Assurance and Quality Control 
  At the beginning of the study, all staff involved was 
trained on how to use the AWARE
TM rapid test kits, the De-
termine HIV1/2 rapid test, and the Enzygnost HIV1/2 Inte-
gral ELISA according to their respective manufacturers’ 
instructions. Sample collection procedures and laboratory 
safety measures were also reviewed and expiration dates of 
all kits checked. In-house controls and kit controls were run 
daily and the environmental temperature at which tests were 
run was noted daily. Results on test strips were read and 
cross-checked by another technician. Ten percent (10%) of 
the samples were selected at randomly during the course of 
the study and retested to ensure accuracy of the testing staff. 
All test results were entered in an excel spreadsheet and later 
on cross-checked for entry errors. 
Statistical Analysis 
  The sensitivity, specificity, positive and negative predic-
tive values of each of the AWARE
TM HIV1/2 Test kits were 
evaluated by using the results of the Determine HIV1/2 rapid 
test and the Enzygnost HIV-1/2 Integral ELISA as the gold 
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the gold standards, the sample set results were excluded from 
the calculation. Sensitivity was calculated as the number of 
HIV-positive samples detected by the assay under evalua-
tion, divided by the total number of confirmed HIV-positive 
samples, multiplied by 100. Specificity was calculated as the 
number of HIV-negative samples detected by the assay un-
der evaluation, divided by the total number of confirmed 
HIV-negative samples, multiplied by 100. The positive pre-
dictive value (PPV) was derived from the true positives (TP) 
divided by the sum of true positives (TP) and false positives 
(FP). The negative predictive value (NPV) was calculated as 
the true negatives (TN) divided by the sum of false negatives 
(FN) and true negatives (TN). All analyses were done in 
Microsoft Excel 2003 and 95% Confidence Intervals were 
calculated in OpenEpi Diagnostic or Screening Test Evalua-
tion 1.0. 
Total Laboratory Cost 
  Cost and end-user analysis of the AWARE™ HIV-1/2 
BSP  and OMT Rapid test kits were compared with other 
commonly used blood and oral fluid test kits found in the 
Cameroon market. Parameters considered included cost of 
the test devices, needed for additional materials and supplies, 
and labor cost. The general safety of the devices in regard to 
the patient, counsellors, and laboratory staff was noted. 
RESULTS 
  The two kits evaluated were based on Immuno-
chromatographic and either used recombinant or synthetic 
peptides from the gp36 and or 41 regions. The gold standard 
included the Enzygnost HIV1/2 Integral, a fourth generation 
ELISA test that detects both HIV antigens and antibodies. Of 
the 732 participants, 248 (34.98 %) and 461(65.02%) were 
confirmed positive and negative, respectively. Of these par-
ticipants, 412 (56.3%) were female. A breakdown of the 
sero-status of the participants and their enrollment location 
are shown in Table 1. Results of 23 participants were discor-
dant between the two gold standard test kits, and were con-
sidered invalid and excluded from the data analysis. 
  Of the 732 samples, 709 (96.9%) matched venous whole 
blood and oral fluid specimens were tested and included in 
the study results (Table 2). All 248 and 461 patients con-
firmed positive and negative blood samples respectively by 
gold standard were equally positive and negative by the 
AWARE 
TM HIV1/2 BSP test kits, thus the diagnostic accu-
racy of the AWARE 
TM BSP test kit was 100% sensitivity, 
specificity, positive and negative predictive values. The 
AWARE
TM HIV1/2 OMT test detected a total of 246 posi-
tive samples, of which 243 were true positives; thus, a sensi-
tivity of 98.8% and positive predictive value of 98%. Simi-
larly, of the 458 negative samples by the AWARE
TM HIV1/2 
OMT test, 453 were true negatives; thus, a specificity of 
98.9%, and negative predictive value of 99.4 % (Table 2). 
The results of a well-characterized archived panel of HIV-2 
(n=7) and HIV-1 group O (n=3) samples using the 
AWARE
TM BSP Rapid test kit gave 100% concordance. 
Table  1.  Overall Sero-Status of Participants Enrolled Per 
Collection Site 
 
Sero-Status Yaounde  Tiko Total 
Confirmed HIV-Positive  128  120   248 
Confirmed HIV-Negative  382  79  461  
Discordant samples between  
gold standard  
20 3    23 
Total 530  202  732 
 
  A laboratory cost analysis between the AWARE
TM test 
kits and other available kits in Cameroon showed that the 
AWARE
TM HIV1/2 OMT had a total per patient cost of 
$4.72 compared to $7.33 + 0.11, the mean cost of other tests 
and was the safest and easiest to use when compared with 
other blood and oral fluid test kits (Table 3). 
DISCUSSION 
  HIV serodiagnosis particularly in resource limiting-
settings has been hindered by several factors, including the 
need for trained personnel, high cost of equipment and rea-
gents, and lack of electricity and laboratory infrastructure 
[21]. This has undermined the importance of current efforts 
to scale-up ARV programs and other HIV preventive meas-
ures within these populations. Our field evaluation of the 
AWARE
TM HIV-1/2 BSP and OMT Rapid test kits using 
samples from Cameroon have demonstrated that these kits 
have high sensitivity, specificity, are easy to use, and thus, 
could serve as POC rapid test, hence circumventing the cur-
rent HIV diagnostic challenges. 
 The  AWARE
TM HIV1/2 BSP rapid test kit was 100% 
sensitive and specific with a 100% NPV and PPV. This is 
consistent with the results obtained in Thailand [22] where a 
sensitivity of 100% and a specificity of 100% were obtained 
in a similar field evaluation of the same test kit. Thailand is 
an area where only the HIV-1 B subtype predominates [23], 
while all HIV-1 subtypes have been shown to co-exist in 
Cameroon including recombinant forms and HIV-1 group N 
which has been reported only in this country [10-15]. The 
consistency in performance of this test kit in these popula-
tions of different viral diversity makes it a reliable tool for 
Table 2.  Summary of Performance of the AWARE
TM Rapid Test Kits 
 
No of Samples   Predictive Value (%) 











(95 CI,%)   Positive (95 CI,%)   Negative (95 CI,%)  
BSP  248   461  0  0  100 (98.5-100)  100 (99.2-100)  100 (98.5-100)  100 (99.2-100) 
OMT  243  453  3  5  98.8 (96.5-99.6)  98.9 (97.1-99.5)  98.0 (95.4-99.1)  99.4 (98.1-99.8) Field Evaluation of Calypte’s AWARE
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HIV testing. In fact, the AWARE BSP test kit had a 100% 
concordance with a panel of well characterized HIV-2 and 
HIV-1 group O samples from Cameroon. These are rare non 
B subtype variants of the HIV that are common in the West 
and Central African countries [24]. This further shows that 
the AWARE
TM HIV1/2 BSP test kit can also be reliably used 
for rapid HIV testing in countries within this sub region. 
 The AWARE
TM HIV1/2 OMT rapid test kit had a sensi-
tivity and specificity of 98.8% and 98.9% respectively in this 
study. Similar field evaluation of the same kit gave sensitivi-
ties and specificities of 100% each in Tanzania [25] and 
99.6% and 100% respectively in South Africa [26]. Despite 
the high viral diversity that has been reported in Cameroon 
and which could have an impact on HIV test kits perform-
ance, current results obtained for the AWARE
TM HIV-1/2 
OMT evaluation still falls within the WHO recommended 
range for test kits to be used for HIV diagnosis [4]. A labora-
tory cost analysis showed that this test kit was the least ex-
pensive, safest and easiest to use compared with other avail-
able test kits. Historically, most countries have structured 
their HIV testing programs using blood-based tests that re-
main the “gold standard” of HIV testing. However, the effec-
tiveness of these traditional blood tests is impaired by issues 
of patient appeal, risk to patients and risk to health care 
workers. The fact that the AWARE
TM HIV1/2 OMT test uses 
oral fluid instead of blood, implies that its sample collection 
technique is non-invasive; thus making it very adaptable for 
use in settings where trained manpower, acceptability and 
collection devices may compromise HIV diagnostic initia-
tives. Despite this, it is important to note here that a recent 
literature search shows that the New York City Department 
of Health and Mental Hygiene (NYC DOHMH) noticed 
some unexplained sporadic false positive results using the 
OraQuick Advance Rapid HIV-1/2 Antibody oral fluid test 
[27]. These findings underscore the importance of confirm-
ing all reactive HIV tests, both from oral fluid and whole-
blood specimens. 
CONCLUSION 
  In summary, this current evaluation shows that both the 
AWARE
TM HIV-1/2 BSP and OMT Rapid test kits per-
formed well on samples from Cameroon, a country with 
complex HIV genetic diversity against a gold standard kit 
which included a fourth generation ELISA that could detect 
both HIV antigens and antibodies. This performance coupled 
with the user friendliness of these kits, suggests that their 
inclusion in the national HIV testing algorithm of this coun-
try will have tremendous impact in scaling up its HIV diag-
nostic program with positive gains in the number of people 
to benefit from ARV drugs treatment programs and other 
care and prevention efforts. Because of these characteristics, 
we also suggest that these kits should further be evaluated in 
other regions of the world particularly in developing coun-
tries where their use could have significant public health 
impact on HIV prevention and clinical management. 
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